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Abstract: 
 
Group 2 innate lymphoid cells (ILC2) are innate immune cells that respond 
rapidly to their environment through soluble inflammatory mediators and cell-
to-cell interactions. As tissue-resident sentinels, ILC2 help orchestrate localized 
type-2 immune responses. These ILC2-driven type-2 responses are now 
recognized both in diverse immune-processes, different anatomical locations, 
and homeostatic or pathological settings. ILC2-derived cytokines and cell-
surface signalling molecules function as key regulators of innate and adaptive 
immunity. Conversely, ILC2 are governed by their environment. As such, ILC2 
form an important nexus of the immune system and may present an attractive 
target for immune modulation in disease. 
 
1. Introduction 
 
In 2010, murine group 2 innate lymphoid cells (ILC2) were formally described 
as a novel innate lymphoid cell (ILC) population that promoted type-2 
immunity1-3. ILC2 are tissue-resident immune cells important for orchestrating 
local type-2 inflammation, found to be enriched at mucosal and barrier 
surfaces4. Functionally, ILC2 are mainly described for their role in promoting 
protective immunity to helminth infections, tissue repair, metabolic 
homeostasis, as well as allergic inflammation5-7. ILC2 belong to a larger family 
of ILC that parallel the adaptive immune system in function, but lack antigen 
specificity (for a review of ILC-lineages, see ref. 8). 
ILC distinctively lack antigen-specific receptors and are activated in an 
antigen-independent manner. This enables ILC to rapidly respond to changes 
in their microenvironment without the need for adaptive immune cell priming9. 
More specifically, ILC express germline-encoded inhibitory or activating 
receptors that regulate their activity, and enables prompt modulation of 
function. This central feature of innate immunity has put forth the hypothesis 
that ILC can instruct the direction of downstream innate and adaptive immune 
responses by providing early polarizing cues. Indeed, Natural Killer (NK) cells, 
in addition to their natural cytotoxic function, are critical regulators of innate and 
adaptive immune functions. NK cells possess rudimentary features of immune 
memory, and can help influence the development of type-1 adaptive immunity, 
but also limit inflammation10,11. Similarly, Group 3 ILC (ILC3) are known to drive 
downstream innate and adaptive immune responses12. Thus, it is clear that 
several ILC lineages have important immune-regulatory functions. 
ILC2 were formally discovered in gut-associated tissues of mice1-3, 
although their presence was previously hypothesized based on the observation 
that T and B cell deficient (recombination-activating gene, Rag1-/- and Rag2-/-) 
mice were able to mount type-2 responses13-15. ILC2 were subsequently 
discovered at other barrier sites, such as the airways and skin, where they 
participated in type-2 inflammation. In contrast to T and B cells of the adaptive 
immune system, ILC2 are sparse in secondary lymphoid organs but enriched 
at mucosal and barrier sites. Moreover, ILC2 are also present in numerous 
other tissues under homeostatic conditions. Parabiosis experiments have 
shown ILC2 to be tissue resident cells that are maintained and expanded locally 
under physiological and pathological conditions16,17. The physical location of 
ILC2 suggests that they may be important in regulating local immune 
responses. In this review we will first summarise ILC2 development and 
identification (see ref. 18 for a comprehensive review), followed by a review of 
their regulation and effector function in different anatomical sites during 
homeostasis and disease. 
 
2. ILC2 development and identification 
 
ILC2 derive from bone marrow haematopoietic stem cells (HSC) in a 
differentiation pathway from common lymphoid precursors (CLP) or lymphoid 
primed multipotent precursors (LMPP). These early precursors are known to 
require ID2, as well as transient NFIL3 expression19, for their development and 
give rise to early innate lymphocyte precursors (EILP), that can differentiate into 
all ILC subtypes, including natural killer (NK) cells18,20. Downstream of 
multipotent EILP are more lineage-restricted progenitors such as the common 
innate helper innate lymphoid precursors (CHILP) that further develop into 
ILC2-lineage restricted progenitors, under the transcriptional control of Id2, 
Zbtb16, Tcf7, Tox, and Bcl11b18,20-23. Current data is consistent with a model in 
which multipotent progenitor cells give rise to unipotent ILC precursors that 
have a more specific cell fate18 (Figure 1). Recently it was observed that a loss 
of the transcription factor (TF) promyelocytic leukaemia zinc finger protein 
(PLZF) (encoded by Zbtb16) has long-term effects on the functional properties 
of mature ILC224. So far, the origin of human ILC2 is still unclear, however it 
was shown that all human ILC subpopulations in secondary lymphoid tissues 
could be derived from a RORγt+ progenitor25. 
As described before and depicted in figure 1, proper development and 
function of ILC2 is dependent on several TFs, including Gata326,27, Rora28,29, 
Gfi130, Tcf731,32, Ets133, and Bcl11b34. However, these TFs are also expressed 
by other lymphoid lineages, which rely on some for their function or 
differentiation. How exactly these different TFs regulate ILC2 differentiation is 
incompletely understood, although individual TFs promote ILC2 reactivity to 
certain alarmins (e.g. IL-25 and IL-33) by upregulating their receptor expression 
and stimulating type 2 cytokine (IL-4, IL-5, and IL-13) production35. GATA3 in 
particular is recognised as a master regulator of type-2 effector genes, cell 
proliferation, and lineage stability35. Importantly, while critical for ILC2 
development and function, GATA3 also has upstream functions in ILC and T 
cell development35-37. While less is known about the regulation of GATA3 in 
ILC2, its expression in Th2 cells is known to depend on IL-4 mediated STAT6 
signalling, as well as TCR and/or IL-2-dependent pathways35. Moreover, Gata3 
in addition to Tcf7 and Bcl11b, have been shown to be Notch-dependent 
targets, this might explain the strong impact of Notch signals in promoting ILC2 
development and differentiation in vitro28,31,38. Phenotypically, mouse and 
human ILC2 can be identified by the absence of surface markers expressed by 
other haematopoietic lineages (lineage-negative), but positive staining for 
CD45 and CD127 (IL7Rα). Without a known ILC2-specific marker, additional 
identifying features must be incorporated for their reliable detection by flow 
cytometry or immunofluorescence microscopy. For mice these markers may 
include surface signalling receptors such as ICOS, KLRG1, CD25, CD117, ST2 
(Il1rl1, IL-33 receptor component) and IL-17RB (IL-25 receptor component), or 
intracellular targets associated with ILC2 function such as GATA3, IL-5, or IL-
13. In mice, gene-reporter animals provide an additional invaluable means to 
identify ILC2. In humans, ILC2-associated markers include CD117, CD161, and 
CRTH239,40, the latter being the receptor for prostaglandin D2, as well as 
GATA3 (See ref. 41 for a more exhaustive list). 
 
In terms of epigenetic regulation, ILC2 effector genes are in a 
constitutive open chromatin conformation that, like their adaptive CD4+ T helper 
2 (Th2) counterparts, is distinct from other ILC or T helper cell lineages9. It has 
recently been shown that the lysine methyltransferase G9a promotes 
expression of ILC2 genes, implicating epigenetic regulation in their lineage 
commitment42. Similarly, post-transcriptional regulation by micro-RNA (miRNA) 
155 was shown to be important for proper ILC2 function in a model of allergic 
airway inflammation43. More recently, it was described that miR-17~92 has 
important implications for ILC2 homeostasis, additionally, miR-17~92-deficient 
ILC2 were shown to be defective in cytokine expression upon IL-33 or thymic 
stromal lymphopoietin (TSLP) induced allergic airway inflammation. Moreover, 
the miR-17~92 cluster member miR-19a was found to specifically promote IL-
5 and IL-13 production, by inhibiting expression of signalling inhibitors, 
including SOCS1 and A2044. Nevertheless, no transcription factor or other gene 
is known to be exclusively expressed by ILC2, thus complicating genetic 
targeting strategies. 
 
3. Regulation of ILC2 activation 
 
As mentioned in the previous section, tissue resident ILC2 do not express 
antigen-specific receptors and are regulated by germline-encoded receptors. 
As such, ILC2 are positioned to integrate local cues from the epithelium, the 
microbiota, other immune cells, and pathogens in their environment to 
modulate inflammation. Non-haematopoietic cell derived type-2 alarmins, 
including IL-25, IL-33 and TSLP are essential for the activation of ILC22,45,46. 
These alarmins, together with other co-regulatory molecules, govern the 
function of ILC2 (see figure 2). 
 
IL-25 
IL-25 belongs to the IL-17 cytokine family, and signals via IL-17RB (in 
conjunction with the shared IL-17RA receptor) and is strongly associated with 
type-2 inflammatory responses. In the airways, epithelial cells have been 
suggested to be able to produce IL-2547, although other cellular sources may 
be present. Administration of IL-25 intranasally induced an IL-25 responsive 
ILC2 population expressing large amounts of the activation marker killer cell 
lectin-like receptor G1 (KLRG1) and IL-17RB, but not ST2. These KLRG1+ 
inflammatory ILC2 are phenotypic distinct from the tissue-resident conventional 
ILC2, proliferated in response to IL-25, but not IL-33, but can develop into ST2+ 
natural ILC248.  
IL-25 plays a more prominent role in activating gut associated ILC249,50, 
where it is particularly produced by epithelial Tuft cells. Although the specific 
stimuli that prompt IL-25 release from Tuft cells are unclear, it is known that IL-
25 driven activation of ILC2 plays a central role in anti-helminth parasite 
immune responses. Interestingly, steady-state ILC2 in the gut produce IL-13, 
enhancing the epithelial-stem-cell compartment to promote a basal level of Tuft 
cell development. In turn, Tuft cells produce IL-25, maintaining ILC2 activation 
in the steady-state gut51,52. During primary helminthic infection, like 
Nippostrongylus brasiliensis, as well as with exposure to the key fungal 
component chitin, the ILC2-Tuft cell-axis is enhanced by Tuft cell 
chemosensory signalling molecule Trpm5 and IL-13 produced by ILC253,54. In 
this model IL-13 enhances Tuft cell differentiation from epithelial precursors in 
the intestine, indicating a positive feedback mechanism between ILC2 and the 
gut epithelium. This further stimulates intestinal goblet cell hyperplasia and 
mucous secretion that is important for parasite expulsion55,56. These data 
provide clear evidence of the importance of IL-25-activated ILC2 primary 
helminth infection and worm expulsion in the gut. 
  
IL-33 
IL-33 is a member of the IL-1 cytokine family but, unlike IL-1β and IL-18, it does 
not require processing by caspases for it to be biologically active57. IL-33 is 
sequestered in the nucleus of cells, and can be released in a passive manner 
during necrotic cell death, acting as an alarmin. However, under conditions of 
apoptotic cell death IL-33 in rendered inactive by proteolytic cleavage by 
caspase-1 and/or caspases-3 and -758. In non-exacerbated asthmatics, IL-33 
is expressed with deletion of exons 3 and 4 (Δ exon 3,4), conferring its cytosolic 
localization and facilitating secretion. This splicing variant form of IL-33 is 
strongly associated with type 2 immunity, whereas full-length IL-33 is not59. 
Moreover, the activity of full-length IL-33 can be further increased through 
alternative proteolytic cleavage after secretion into the extracellular milieu60. 
Although IL-33 is constitutively expressed in the nucleus of many cell types, 
expression can be further increased during inflammation. Upregulation of IL-33 
protein has been observed in alveolar type II epithelial cells upon exposure to 
ovalbumin, chitin, or Alternaria alternata61-63. 
IL-33 is known to activate ST2+ ILC2, initiating an innate type 2 
inflammatory response, through the production of IL-5 and IL-13. In the lung 
several allergens, like house dust mite (HDM), Alternaria alternata, and papain 
have also been reported to stimulate lung ILC2 via the release of IL-3364-66. IL-
33 stimulation induces NF-κB p65, JNK, and p38 MAPK, the latter which 
subsequently induces phosphorylation of GATA-3 in ILC2. Phosphorylation of 
GATA3 by p38 strongly increased GATA3 binding to the Il5 and Il13 promotors, 
but not IL-6, and interestingly p38 MAPK inhibition during early phase of 
stimulated significantly suppressed IL-33-induced production of IL-5 and IL-
1367. Recent work in mice has revealed that in the very early post-natal stages 
type 2 immunity is mediated by elevated IL-33 expression in the lung, which is 
dependent on ILC2 but not CD4+ T cells68. In adult mice, IL-33 and T cell-
derived IL-2 expanded ILC2 populations in the lung in a model of N. brasiliensis 
infection that led to larval damage69. The release of IL-1β primes ILC2 to further 
increase their responsiveness to IL-33 and IL-2570,71. Recently, ATP-activated 
mast cells in the gut were found to increase ILC2 activation in part through 
increased IL-33 production72. In an indirect mechanism, IL-33 activated mast 
cells in the lung may activate ILC2 through production of lipid mediators, like 
leukotriene D4 and prostaglandin D2, as discussed in more detail below73. 
ILC2 engagement by IL-33 induces the activation of ERK signalling 
pathway, which is negatively regulated by Sprouty-related Ena/VASP homology 
1 domain-containing protein 1 (Spred1). Spred1 suppresses both secretion of 
type-2 cytokines as well as proliferation apoptosis of ILC2 via the stabilization 
of GATA-3. As Spred1 is highly expressed in IL-33 activated lung ILC2, Spred1 
may be involved in a negative feedback loop affecting IL-33-activated ERK 
signalling pathway74. Induction of IL-33 and TSLP by lung epithelial cells after 
chitin exposure or helminthic infection has further been reported to induce an 
interferon regulatory factor 4 (IRF4)-IL9 program in ILC2, that promotes rapid 
IL-5 and IL-13 production required for optimal epithelial responses75. Moreover, 
constitutive expression of IL-9 by ILC2 after IL-33 (and TSLP) exposure can act 
in an autocrine manner to prolong survival of ILC2 in the tissue and prevented 
apoptosis of these cells, thereby enhancing ILC2-induced type 2 immune 
responses76,77. In general, IL-33 is recognized as the main cytokine activating 
ILC2, however it becomes increasingly clear that there are many other soluble 
and non-soluble factors implicated in ILC2 activation. 
 
TSLP 
TSLP is suggested to be expressed mostly by epithelial cells and keratinocytes 
in the skin, gut, and lungs, although DCs,  mast cells, and basophils may also 
provide a cellular source for this cytokine78. A recent study revealed a 
subpopulation of tuft cells as another potential source of TSLP in the small 
intestinal epithelium79. TSLP is linked to multiple type-2 related diseases, such 
as atopic dermatitis, asthma, and allergic responses. TSLP is an IL-7-like 
cytokine and binds the TSLP receptor, which forms a heterodimer with IL-7Rα, 
and is expressed on ILC2, Th2 cells, DCs, and mast cells80. In contrast to the 
ILC2 populations in the lung and gut, which are critically dependant on IL-25 
and IL-33 for their activation, skin and skin draining lymph node ILC2 were 
found to be independent of these canonical cytokines, but instead were 
activated primarily by TSLP81. Recent studies have suggested that TSLP can 
contribute to ILC2 activation promoting corticosteroid resistance in the context 
of IL-33 induced allergic airway inflammation82,83.  
 In humans TSLP-stimulated ILC2 were shown to upregulate GATA-3 
and produce type-2 cytokines IL-4, IL-5, and IL-1327. Moreover, treatment of 
mild allergic asthmatics with an anti-TSLP monoclonal antibody (AMG 157) 
resulted in a significant reduction of allergen-induced airway eosinophils and 
bronchoconstriction84. These results indicate that TSLP serves an important 
role for ILC2-activation; however, it remains uncertain whether TSLP is a 
master switch in ILC2 activation or it is part of a concerted action by several 
parallel pathways. 
 
Other cytokines that regulate ILC2 
Apart from the canonical ILC2 activating cytokines, IL-25, IL-33, and TSLP, 
other cytokines are also capable of inducing ILC2 responses, such as IL-2, IL-
4, IL-7 and IL-9. IL-2 is known to be important for ILC2 survival and serves as 
a major co-factor in regulating ILC2 function during type-2 immunopathology in 
the lung. Indeed, while IL-2 alone was found to be insufficient to increase in 
vivo IL-13 production by ILC2, synergy between IL-2 and IL-33 did augment Il-
13 expression by ILC285. Nevertheless, in vivo IL-2/anti-IL2-mAb treatment is 
commonly used to expand ILC2 in mice. It is likely that T cell derived IL-2 
synergises with type-2 alarmins to promote ILC2 activation86. Similarly, IL-7 can 
synergize with IL-33 to promote ILC2 activation in vitro27,64. Moreover, mice 
defective in IL-7 signalling are ILC2-deficient, indicating the importance of this 
cytokine for either ILC2 development and/or homeostasis1,87,88. IL-9 also has a 
co-stimulatory function on ILC2, enhancing their survival77. Lastly, basophil or 
eosinophil derived IL-4 is known to influence ILC2 by enforcing ILC2 lineage 
stability, proliferation, and function70,89. Importantly, these cytokines require the 
common gamma (cγ) chain as part of their receptors, and cγ chain-deficient mice 
or humans90 lack ILC2. Importantly, ILC2 function can also be negatively 
influenced by both type I and type II interferon, as well as IL-27 signalling17,70,91-
93. Suppression of ILC2 function by these cytokines has been shown to rely on 
the transcription factor STAT117,94. Finally, ILC2 lineage plasticity and trans-
differentiation can be induced by IL-1β, IL-12 and IL-18 70,71,95,96. 
 
Receptor-ligand interactions 
In addition to the soluble factors that regulate ILC2, a number of receptor-ligand 
interactions have been shown to mediate ILC2 activation. Tumor necrosis 
factor member TL1A (Tnfsf15) is expressed by endothelial cells and myeloid 
cells and binds DR3 expressed by T cells and ILC2. TL1A-DR3 interaction 
leads to ILC2 proliferation and their expression of IL-5 in-vivo and in-vitro97,98. 
The presence of IL-7 was shown to enhance this response, but well below that 
induced by IL-33. Like the mouse system, also in humans TL1A is less potent 
than IL-33 and IL-25 but acts synergistically with both factors to drive an optimal 
ILC2 response. Human ILC2 have further been described to express NKp30 
that upon interaction with its cognate activating ligand B7-H6 induces rapid 
production of type-2 cytokines. Interestingly, higher levels of B7-H6 expression 
where observed in lesions of AD patients99.  
In the lungs of allergic mice, ILC2 were found to express ICOS (as well 
as ICOS-ligand), interaction of ICOS with its ligand was observed to promote 
cytokine production, proliferation, and survival of ILC2 through STAT-5 
signalling100,101. In contrast, KLRG-1 expression and its binding to E-cadherin 
have been shown to inhibit human ILC2 function102. 
 
Lipid mediators 
Although generally involved in metabolism, bioactive lipids can influence key 
physiological mechanisms and cell signalling in mice and humans103. The first 
lipid mediator described to regulate ILC2 function was Leukotriene D4 (LTD4) 
which has very high affinity for the receptor CysLT1R. As ILC2 endogenously 
express this receptor, LTD4 induction, by Alternaria alternata challenge, 
promoted accumulation, enhanced proliferation, and robust production of IL-4 
and IL-5 by ILC2104. Similarly, Leukotriene C4 (LTC4) given in combination with 
IL-33 has been shown to directly potentiate IL-5 and IL-13 production by ILC2, 
via activation of the CysLT1R105. Interestingly, human ILC2 also express the 
pro-resolving receptor ALX/FRP2 which binds the resolvin lipoxin A4. Lipoxin 
A4 has anti-inflammatory properties and inhibits IL-13 production by human 
peripheral blood derived ILC2 co-cultured in the presence of IL-2, IL-25, IL-33, 
and PGD2106. 
The eicosanoid prostaglandin D2 (PGD2) is the key prostaglandin driving 
type-2 inflammation and its receptor (CRTH2) is selectively expressed on Th2-
cells and human ILC2. PGD2-CRTH2 signalling was shown to induce ILC2 
migration and IL-4 production, as well as potentiate IL-25 and IL-33-mediated 
responses107. In mice, PGD2 was also shown to drive ILC2 function and 
accumulation in the airways73. Notably, the inhibitory prostaglandin I2 (PGI2), or 
prostacyclin, has been suggested to attenuate allergic inflammation when 
ligated to its receptor (IP)108. PGI2 has been shown to inhibit human and mouse 
ILC2 responses, as IP ligation blocked ILC2 proliferation and induced 
apoptosis. Furthermore, IP-deficient mice displayed higher IL-5 and IL-13 
expressing ILC2 in the lung after Alternaria alternata challenge109. 
Recently, a study by Von Moltke and colleagues reported that, although 
largely dispensable for homeostasis, leukotrienes, and especially LTB4 and 
cysteinyl LTs, play a nonredundant role for in activating the ILC2 which was 
shown to be dependent on NFAT signalling and worked in synergy with IL-33110. 
Interestingly, mucosal neuron derived neuromedin U (NMU) also results in the 
activation of ILC2 and immediate production of type 2 cytokines downstream of 
the NFAT signalling cascade111. Showing the wider importance of NFAT 
signalling in ILC2 activation. 
 
Hormones 
Transcriptional profiling of innate lymphoid cells has revealed that the androgen 
receptor (AR) is a prototypical ILC2 signature gene in tissue-resident ILC2112. 
This may suggest a role for hormones in the regulation of ILC2 function. Recent 
data has revealed that the development of ILC2 is greatly influenced by 
expression of the AR on progenitor ILC2. Engagement of the AR by its ligands, 
the male hormone androgen, inhibits differentiation of ILC2 progenitors into 
mature ILC2113. These data demonstrate that that androgen-signalling can 
regulate ILC2 development, however, as very few ILC2 develop from 
progenitors in adult mice16, it may well be that AR-signalling imprints on steady-
state numbers of ILC2. 
 Other hormones, like estrogen, have also been linked to airway 
hyperreactivity, although only in steady-state as no differences were observed 
between wild-type and ERα-/- mice after allergen challenge114. However, this 
study does not specifically target ILC2. In all, very little is known about the 
hormonal control of ILC2. 
 
Neuronal regulation 
Neuronal control of ILC2 activation presents another dimension of immune-
regulation. Recently it was found that the neurotransmitter Adenosine, an ATP 
catabolite binding the Adenosine receptor, has recently been suggested to 
negatively regulate type-2 cytokine production by ILC2115. Others have 
described that ILC2 selectively express neuromedin U receptor 1 (Nmur1) and 
ILC2 in the mouse gastrointestinal tract, as well as the lung, co-localize with 
cholinergic neurons that express the neuropeptide NMU111,116. Very similar to 
data obtained in ILC3, where neurons were shown to interact with ILC3 and 
regulate their cytokine expression117. Interestingly, single-cell RNA sequencing 
data from IL-25 and IL-33 stimulated lung ILC2 revealed the Nmur1 was 
preferentially expressed during steady state and after IL-25 stimulation118. It 
was shown that NMU controls ILC2s downstream of the activation of calcineurin 
and NFAT111. In vitro, as well as in vivo stimulation of ILC2 with NMU induced 
rapid cell activation, proliferation, and secretion of type-2 cytokines, resulting in 
accelerated clearance of nematode Nippostrongylus Brasiliensis111,116. 
Additionally, the circadian synchronizer vasoactive intestinal peptide (VIP) 
activates ILC2 by binding its receptor VPAC, stimulating IL-5 release and 
linking eosinophilic inflammation with metabolic cycling87 These studies very 
elegantly present evidence of a selective mechanism by which enteric neurons 
can provide neuro-immune crosstalk and promote rapid type-2 immune 
responses at mucosal barriers. 
 
4. Effector molecules produced by ILC2 
 
As tissue-resident innate immune cells, ILC2 are positioned to rapidly respond 
to stimuli. Upon activation ILC2 can express various soluble or membrane-
bound effector molecules. These include the well-established IL-4, IL-5, IL-9, 
IL-13, and amphiregulin (see figure 2), but also others inflammatory molecules 
such as IL-6, IL-8, IP10, methionine-enkephalin (MetEnk)27,119. Moreover, ILC2 
express surface-bound molecules such as MHC class II, CD80/86, ICOSL and 
OX40L that may participate in immune-regulatory functions. 
 
Cytokines 
Initial identification of ILC2 was made possible by their expression of type-2 
effector cytokines1-3. While Il4-egfp reporter activity marks naïve ILC2, protein 
expression is observed only in activated ILC23,104. Nevertheless, ILC2-derived 
IL-4 plays a role in polarising Th2 cells during helminth infection120, and may 
also block the generation of allergen-specific Treg cells, thereby promoting food 
allergy121. In comparison to relatively scant production of IL-4, ILC2 are a potent 
cellular source of IL-13. Rapid secretion of IL-13 by ILC2 influences both 
immune and non-immune cells. Myeloid cells including macrophages and 
dendritic cells are activated by IL-13 to become polarised to a M2 or type-2 
chemokine secreting phenotype respectively. ILC2-derived IL-13 also activates 
endothelial and epithelial cell-types to express adhesion molecules or enhance 
the secretion of mucous from goblet cells. Importantly, IL-4 and IL-13 share 
common signalling components, and the overlapping roles of ILC2-derived IL-
4 and IL-13 is not yet understood (for more details, see review on IL-4/13 by 
Wynn et al.122). ILC2 are the main innate source of IL-5, a growth factor 
essential for eosinophil homeostasis87. The transcript for Il5 is constitutively 
expressed by a significant proportion of ILC2 in many anatomical locations, 
making the Il5-tdTomato reporter mouse an attractive model for ILC2 
identification. 
Although ILC2 can respond to IL-9, they are also an important source of 
this cytokine, leading to an autocrine signalling module, as depicted in figure 
2) that enforces IL-5 and IL-13 production76. While this feed-forward axis is 
essential for lung inflammation, IL-9 producing ILC2 were found to resolve 
inflammation in a model of allergen-induced arthritis, through the activation of 
Treg cells123. This implies that IL-9+ ILC2 can yield different outcomes 
depending on their location and the inflammatory microenvironment. Although 
very little is known about ILC2 Treg cell interaction, ILC2/Treg crosstalk has 
also been observed in studies focussing on helminth expulsion124. Furthermore, 
within the visceral adipose tissue and lung tissues ILC2 and Treg cells were 
shown to localize to similar areas under homeostatic conditions, as well as in 
multiple other tissues after IL-33 stimulation91. Interestingly, after IL-33 
administration or N. brasiliensis infection ICOS-L+ ILC2 and ICOS+ Treg cells 
were found to accumulate in tissues, whereas Treg expansion in ICOS-L-
deficient mice or after treatment with ICOS-L monoclonal antibodies was 
impaired91. Suggesting that ICOS-L expression by ILC2 could promote Treg 
cell accumulation and provide a mechanism for ILC2 to communicate with Treg 
cells. Interestingly, a novel gut-resident ILC subset that secretes IL-10 has 
recently been described125, while another recent study identified IL-10 
production in alternatively activated ILC2126. 
ILC2 act mainly through secreting soluble mediators. Given the fact that 
ILC2 are tissue-resident cells, their release of effector molecules in the 
microenvironment might be just the desired response for efficient signal 
transduction and amplification within the tissue. Apart from the classical type-2 
cytokines, other ILC2 effector molecules have been described. For example, 
ILC2 are a main cellular source of amphiregulin, important for post-infection 
wound repair as well as for restoring epithelial integrity and lung function127. 
Additionally, there is MetEnk that was suggested to be an ILC2 effector 
mechanism to regulate metabolic homeostasis by eliciting beiging of white 
adipose tissue after IL-33 stimulation119. Lastly, ILC2 are also able to produce 
IL-285, which as with IL-9, may function in an autocrine or paracrine fashion. 
In all, the effector molecules produced by ILC2 will in part be overlapping 
with T cells; however, there will also be unique functions for ILC2 secreted 
molecules that need to be further defined using specific ILC2 depletion 
strategies. 
 
Immune-regulatory cell-surface molecules 
In addition to soluble mediators, ILC2 can interact with other cells via surface 
bound molecules. ICOS and KLRG1 are among the few molecules that can 
interact with surface-bound ligands. KLRG1 has, in the context of atopic 
dermatitis, been shown to act as an inhibitory receptor on ILC2, reducing 
proliferation and expression of GATA3, as well as IL5 and IL13 gene transcripts 
upon E-cadherin ligation102. Interestingly, both ICOS and ICOS-L are co-
expressed on ILC2 and cognate interaction between ICOS-ligand on ILC2 and 
ICOS on T cells, after IL-33 stimulation, has been proposed to mediate Treg 
accumulation91. Additionally, ICOS/ICOS-L interaction on ILC2 were found to 
influence STAT5 signalling, promoting ILC2 proliferation and function in a 
model of allergic airway inflammation100. IL-33 has further been shown to 
upregulate OX40 ligand (OX40L) expression on ILC2, which was suggested to 
promote adaptive immunity by co-stimulation of T cells128. Additionally, OX40-
OX40L ligation has further been shown to enhance Th2 cell expansion and 
survival129,130. Other surface molecules include programmed death 1 (PD-1) 
receptor, its ligand PD-L1, and MHCII. PD-1 has recently been found to be 
upregulated on activated ILC2, and depletion of these PD-1+ ILC2 reduced 
papain induced lung inflammation131. Intriguingly, ILC2 can also express PD-
L1, which functions to promote CD4+ Th2 cell responses132. The expression of 
MHCII, and CD80 and CD86 by mouse ILC2 allows for cellular interaction with 
CD4+ T cells. MHCII+ ILC2 have an ability to induce Th2 cell differentiation in 
vitro from naïve CD4 T cells, while MHCII-deficient ILC2 experiments indicate 
a role for enhancing Th2 cell-driven helminth expulsion in vivo86,128. 
 
5. ILC2 immune function 
 
Adipose tissue 
ILC2 are enriched in adipose tissue, where they were initially identified in 
murine white adipose fat-associated lymphoid clusters1,133. White adipose 
tissue (WAT) ILC2 can regulate eosinophil and alternatively activated 
macrophages (AAMs) responses134. AAMs produce norepinephrine in 
response to eosinophil derived IL-4, which leads to a beneficial caloric balance 
and beiging of WAT135. More recently, Artis and colleagues showed that IL-33 
administration resulted in elevated numbers of ILC2 in WAT, which was 
associated with an increase in beige adipocytes, improved glucose tolerance, 
and increased weight loss119. Concurrently, it was shown that ILC2 and beige 
adipocyte numbers were reduced in WAT of Il33-/- animals, while reconstitution 
of alymphoid mice with ILC2 was sufficient to promote WAT beiging, 
independent of the adaptive immune system, eosinophils, or IL-4 receptor 
signalling. Although recently others have demonstrated that AAMs do not 
synthesize relevant amounts of norepinephrine in response to IL-4 and 
subsequently failed to induce expression of thermogenic genes, like Ucp1, in 
adipocytes136. Therefore, the role of AAMs in adipocyte metabolism or adaptive 
thermogenesis is still subjected to some controversy. ILC2 were further 
reported to produce MetEnk peptides, leading to the upregulation of Ucp1 by 
adipocyte (in vitro) and promoting beiging in vivo119. MetEnk treated animals’ 
upregulated the beige adipocyte marker Ucp1 in an IL-4 and IL-13 independent 
manner, as neither cytokine expression changed upon MetEnk 
administration119. However, using tissue specific deletion of IL-4Rα, Chawla 
and colleagues showed that IL-4 could act directly on PDGFRα+ adipocyte 
progenitors to regulate genes associated with beige adipocyte differentiation, 
such as Ucp1, Klhl13, Tnfrsf9, and Tmem26 bypassing the 
AAM/norepinephrine axis137,138. They also found that ILC2 derived IL-13, in 
synergy with eosinophil derived IL-4, might directly act on adipocytes, through 
IL-4Rα signalling, to promote beige adipocyte development137. These studies 
suggest that ILC2 can interact with various cell types within the adipose tissue 
to support metabolic homeostasis.  
Interestingly, there is also evidence that the neuropeptide VIP, which is  
regulated by caloric intake, increased IL-5 production by ILC2 enhancing 
eosinophil responses associated with a lean state in mice87. Additionally, the 
ability of ILC2 to sense vitamin A deficiency suggest that ILC2 can respond to 
dietary factors in maintaining metabolic homeostasis139. In all, these studies 
offer important insights in the role of ILC2 in homeostasis, as well as their 
potential to be involved in metabolic disease. 
 
Airways 
Type 2 immune responses are typically seen as the hallmark of allergic airway 
inflammation140. Genome-wide association studies of asthmatic patients have 
identified many ILC2 associated genes, such as: RORA, IL-33, IL1RL1, and IL-
13141. While ILC2 are the most prevalent innate lymphoid cells in the lungs of 
naïve mice, they remain a relative rare population among immune cells127.  
The emerging role of ILC2 in the development of allergic airway 
inflammation has been studied in various mouse models, using extracts of 
HDM64,142 (more recently in combination with polutants143), protease containing 
allergens (papain64 and Alternaria alternata49), ovalbumin144, or chitin75. Early 
studies have linked ILC2 to the pathogenesis of allergic airway inflammation as 
treatment of Rag1-/- mice (which lack adaptive immune cells) with papain 
induced airway inflammation accompanied by eosinophilic infiltration and 
mucus overproduction64, a feature previously primarily associated with Th2 
cells. Moreover, A. Alternata exposure has been reported to cause IL-33 
dependent exacerbated disease in mice sensitized with an alternative 
allergen145, which together with work on ILC2-memory146 suggests that antigen-
independent activation of ILC2 can contribute to type-2 airway diseases. 
Similarly, administration of chitin or infection with the intestinal nematode 
Strongyloides venezuelensis triggered the production of IL-33, which lead to 
the activation of ILC2 in the lung and caused pulmonary eosinophilia147. 
Thus, ILC2 are indirectly activated by allergens via airway epithelial 
cells64,148 (or other sources of the prototypical type-2 alarmins: IL-33, IL-25, and 
TSLP49,64,144). While administration of these alarmins has the ability to induce 
ILC2-driven lung inflammation, IL-33 appears to be the most prominent 
physiological stimulus in the airways149,150, whereas IL-25 is regarded to be a 
more prominent ILC2 activator in the gastrointestinal tract2. Interestingly, 
intranasal administration of recombinant IL-25 promotes the emergence of an 
IL17RB+KLRG1hi ILC2 population in the lung48. Although these cells are at first 
ST2-, they may convert into ST2+ ILC2 in the lung, suggesting that the tissue-
specific microenvironment may strongly influence lung ILC2 regulation.  
 
Lung ILC2 immune regulation 
While ILC2 are the primary source of innate IL-5 and IL-13, the relative 
contribution of ILC2 versus that of Th2 cells in asthma has remained elusive. In 
wild-type mice, ILC2 can constitute over half of the cytokine producing immune 
cells after HDM or OVA exposure144, while other studies have reported that 
ILC2 are redundant in the presence of Th2 cells45. Furthermore, the findings 
that effector Th2 cells are readily activated by type-2 alarmins in the absence 
of antigen151, and that ILC-deficient patients experienced no increase in 
disease90, provokes discussion about the importance of ILC2. Nevertheless, 
studies using ILC2-targeted mouse models are revealing mechanisms by which 
ILC2 can modulate adaptive immune function in the airways.  
ILC2-deficient mice, generated by bone marrow transplantation using 
Rorasg/sg (Rora-/-) donors, revealed that ILC2 activity was essential for efficient 
Th2 cell differentiation following airway exposure to allergen29,86,142. Several 
mechanisms contribute to interactions between ILC2 and CD4+ T cells; direct 
antigen-presentation by MHCII+ ILC2 to naïve CD4+ T cells and cell-to-cell co-
stimulation promote Th2 cell activation and differentiation86,128,152,153. ILC2-
derived IL-13 also indirectly influences Th2 cell differentiation by promoting LN 
homing of lung dendritic cells65. Recruitment of Th2 cells into the lung tissue 
also influenced by ILC2/DC crosstalk-driven CCL17 chemokine production154. 
In addition to regulating Th2 cells, ILC2 can also modulate ICOS-L+ Treg cells 
in the lung through induction of ICOS expression91. Conversely, Treg cells may 
also suppress ILC2 cells to limit allergic airway inflammation155. Importantly, 
novel reagents that more selectively target ILC2 are essential to understand 
their precise function as immune-regulatory cells45,86,154. Nevertheless, it is 
clear that ILC2 are able to work in concert with adaptive immune cells, although 
the relevance of these interactions in human disease will need to be 
established. 
 ILC2-derived IL-13 is known to influence innate type-2 lung 
inflammation by promoting eosinophilia and macrophage activation. 
Interestingly, recent data using these mice suggests that IL-13 production by 
IL-33 activated ILC2 contributes to asthma pathogenesis by increasing 
bronchial epithelial tight-junction barrier leakiness156. Moreover, work on 
neonatal mice revealed a profound increase in lung IL-33 after birth, which was 
associated with ILC2 proliferation and IL-13-mediated M2 macrophage 
polarisation68,157,158. These observations suggest that in early postnatal stages, 
type 2 immunity is established by IL-33-driven recruitment of inflammatory cells, 
in part via ILC2. Interestingly, exposure to antigens during this neonatal period 
resulted in the development of allergic airway inflammation, which was 
minimally dependent on Th2 cells, confirming an important role T-cell-
independent activation of lung inflammation by ILC268. Another recent paper 
highlighted the importance of ILC2 cell-intrinsic metabolism. In this study both 
mouse and human ILC2 were shown to express arginase-1 and arginine 
metabolism was found to control ILC2 proliferation and their production of type-
2 cytokines. Ultimately suggesting that arginine metabolism within ILC2 is able 
to promote type 2 allergic lung inflammation159. 
In patients, ILC2 have been detected in blood and sputum of mild and 
severe asthmatics, where they could promote the persistence of eosinophilic 
inflammation160.  However, frequencies of circulating ILC2 in PBMCs were not 
found to be different between allergic patients and non-allergic controls161. 
Interestingly, higher numbers of circulating ILC2 observed in patients that 
presented with signs of allergic asthma compared to non-asthmatic allergic 
patients162. Moreover, the frequency of IL-13 producing ILC2 was found to be 
significantly higher in patients with uncontrolled asthma, whereas it was 
decreased dramatically when these patients had their symptoms controlled by 
treatment163. Apart from identifying ILC2 as being possible predictors of asthma 
control, several studies have suggested these cells as possible therapeutic 
target. Recent data has shown that dexamethasone exposure attenuated the 
production of type-2 cytokines by ILC2 and Th2 T cells after IL-33 stimulation164. 
Although others have reported allergen induced TSLP production makes ILC2 
resistant to steroid-induced cell death through STAT5 activation82 and indeed 
neutralization of TSLP has been shown to be effective in mild asthmatics84. 
Finally, the DP2 receptor (CRTH2) inhibitor, fevipiprant, has been shown to 
reduce eosinophilic airway inflammation in patients with moderate-to-severe 
asthma, despite inhaled corticosteroid treatment165. 
Taken together, these data present an important role for ILC2 not only in the 
initiation of allergic airway inflammation, but also in fostering a network of 
cellular responses and interactions with many other cell in the lung to propagate 
the allergic immune response. 
 
Role of ILC2 in viral induced infection 
Besides their role in allergic lung inflammation, ILC2 also contribute to airway 
hyper responsiveness in response to respiratory viruses, like influenza, 
rhinovirus (RV), or respiratory syncytial virus (RSV) infection in adult and 
neonatal mice and humans, respectively166,167. Viral infections can damage the 
airway epithelium and induce type-2 immune responses via the activation of 
epithelial cells and their subsequent production of IL-25 and IL-33. RV infection 
induced epithelial IL-25 production has been shown to augment allergen-
induced IL-25 production in mice and subsequently mediate RV-induced 
asthma exacerbations168. In addition, influenza studies report that activation of 
ILC2 during pandemic H1N1, or H3N1 influenza A viral infection results in a 
rapid development of airway hyper responsiveness (AHR) in an IL-33-
dependent manner166,169. Others have shown that enhanced ILC2 activity, in 
the absence of IFNγ17,93, characterized by increased production of IL-5 and 
amphiregulin, exhibited decreased susceptibility to lethal infection with H1N1-
influenza93. Studies in immature mice have shown that IFNγ inhibits ILC2 
expansion and IL-13 production thereby attenuating RV-induced goblet cell 
metaplasia and demonstrating the antagonistic function of IFNγ on ILC2 
expansion and gene expression170. Moreover, deficiency in signalling through 
the type I interferon receptor has been shown to lead to elevated activation of 
ILC292. This type I interferon-mediated inhibition of ILC2 proliferation and 
cytokine release was further suggested to be dependent on the heterotrimeric 
ISGF3 complex consisting of STAT1, STAT2, and IRF917,92,94. Interestingly, 
influenza-virus-induced inflammation in a model of COPD exacerbation initiates 
ILC2 plasticity. The observed conversion of ILC2 was accompanied by a 
significant reduction in GATA-3 expression and the exposure to 
microenvironmental cues, such as IL-12 and IL-1896. 
 During RSV infection, early TSLP-dependent activation of ILC2 resulted 
in the production of IL-13 and the subsequent development of AHR and mucus 
accumulation, in the absence of eosinophilia171. However, as in other models, 
IL-33 was also elevated in the lungs during RSV-infection and airway 
inflammatory responses were reduced in IL-33 KO mice, clearly showing that 
both TSLPR and IL-33R signalling pathways play an important role in the viral 
induction of type-2 immunity172.  
 Interestingly, following acute influenza viral infection, accumulation of 
ILC2 is not only associated with immunopathology, but also with tissue repair 
and restoration of tissue integrity. Tissue repair functions of ILC2 were IL-13 
independent, but relied on their production of amphiregulin127. Together these 
studies show that although ILC2 may have immunopathological roles during 
viral infection, they could seemingly induce opposite pathways restoring lung 
homeostasis and tissue repair after lung injury. 
 
Skin 
Atopic dermatitis (AD) is an inflammatory skin disease characterized by 
epithelial barrier dysfunction and often associated with a type 2 immune 
response to common environmental allergens, as shown by the high levels of 
IL-4 and IL-13 found in skin lesions of AD patients173. Genes linked to 
susceptibility to atopic disease, such as TSLP, IL-4, IL-5, and IL-13, are also 
associated with ILC2 responses174. Most data regarding the role of ILC2 in 
atopic dermatitis has been derived from mouse models and these have shown 
that skin-resident ILC2 responses can be elicited by TSLP, IL-25, and IL-33, 
the vitamin D analog calcipotriol, and complexes of IL-2 with anti-IL-2 
mAb81,102,175,176. Moreover, TSLP activates a population of skin-resident ILC2 
in healthy mouse and human skin, which are also enriched in dermal lesions of 
human AD patients, independent of IL-33R or IL-25R signalling81. Others have 
shown that mice expressing IL-33 under the keratin 14 promoter develop a 
spontaneous AD-like inflammation of the skin, associated with the infiltration of 
IL-5+ ILC2176. suggesting that depending on the specific micro environmental 
cues ILC2 get differentially activated to produce type-2 cytokines and cooperate 
in AD pathogenesis. However, besides their pathological role in dermal 
inflammation, IL-33 activated ILC2 have been shown to harbour a protective 
tissue reparative role during cutaneous wound healing177.  
Skin lesions of AD patients, but not psoriasis, have been shown to be 
enriched for ILC2 producing IL-5 and Il-13, in addition to amphiregulin (which 
mediates tissue repair)178. Furthermore, the discovery that E-cadherin-KLRG1 
ligation on human ILC2 shows a clear reduction in IL-5 and IL-13 production 
and the fact that E-cadherin is characteristic of filaggrin insufficiency, suggests 
that both mechanisms may cooperate in AD immunopathogenesis102. However, 
it is to note that only half of the AD patients carry filaggrin mutations and of 
those 40% do not progress to allergic sensitization and the development of 
AD179,180. Even if filaggrin deficiency and its role in barrier dysfunction on its 
own may not be sufficient to cause AD lesions, the absence of additional E-
cadherin ligation on ILC2 may favor type 2 immune responses and the 
development of AD skin lesions. Moreover, ILC2 have been demonstrated to 
be the predominant IL-13-producing cell population in the skin and elevated IL-
13 levels in the skin predispose mice for the development of skin lesions175,176. 
Therefore, there has been great interest in blocking IL-13 as therapeutic 
intervention strategy. The blocking of IL-13 activity, in humans, through 
dupilumab has been shown to alleviate the symptoms of atopic disease59.  
Together data from GWAS of patients and data collected from human studies 
and mouse models suggest skin-resident ILC2 to play a prominent role in the 
pathogenesis of AD; although additional work is awaited to elucidate the exact 
role of ILC2 in the skin. 
 
The role of ILC2 in other anatomical sites 
It is becoming increasingly clear that ILC2 are not restricted to mucosal barrier 
sites, but are present in numerous other tissues. In the liver, ILC2 have been 
associated with IL-33-induced liver fibrosis. It is demonstrated that IL-33 
released by stressed hepatocytes activates ILC2, which trigger the IL-13 
dependent profibrogenic activation of hepatic stellate cells181,182. IL-33 is further 
elevated in models of viral hepatitis, however, in this model ILC2 have been 
suggested to limit liver injury183.  
 ILC2 have also been found in the brain meningeal space, where they 
respond to spinal cord injury by the production of type-2 cytokines184. In 
addition, brain-resident ILC2 were found to polarize the immune response to 
cerebral malaria185. ILC2 in the nervous system may also play a role in multiple 
sclerosis. As ILC2 found to accumulate in the brain and draining lymph nodes 
of mice resistant to experimental autoimmune encephalitis186.  
 Although far from exhaustive the implications of ILC2 in the diseases 
described above and their discovery in numerous mucosal and non-barrier 
tissues implicates the importance to consider these cells in an increasing 
number of organs and diseases. 
 
6. Conclusion & future directions. 
 
Since their discovery as an innate source of type-2 cytokines in the gut, ILC2 
have been identified in an expanding number of other anatomical locations. 
Their tissue-residency reflects their sentinel function, and role in tissue 
homeostasis. It is becoming increasingly evident that ILC2 are intricately 
involved in regulating both immune and non-immune cell types. Conversely, 
ILC2 function is tightly modulated by diverse upstream factors. As such, it is 
likely that ILC2 are an important tissue-specific nexus between immune and 
non-haematopoietic cells in type-2 immunity. Importantly, findings of mouse 
ILC2 biology will need to be translated into humans to resolve their importance 
in disease.  
Nevertheless, intriguing findings in murine models show that ILC2 are 
essential in the initiation and propagation of allergic type-2 immune responses 
from birth to adulthood. The identification of ILC2 and the further insight into 
their function in inflammation and tissue repair has highlighted the important 
role of this type of innate lymphoid cells in triggering immunity. Recent mouse 
and human data together allow us to become increasingly aware of the fact that 
ILC2 responses are greatly influenced by their interactions with microbiota, 
nutrients, metabolites, neurons, and stromal cells. However, specific 
microenvironmental factors mediating the plasticity of ILC2 have not been 
identified and the molecular mechanisms underlying ILC2 interaction with their 
environment remain poorly understood, although the use of transcriptomic 
datasets can further enable investigations into this issue112. It is expected that 
future studies will provide more detailed answers to the remaining outstanding 
questions and lead to the development of novel and effective therapy for ILC2-
driven diseases. 
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Figure legends 
 
Figure 1. Innate lymphoid cell development from progenitors. Downstream of 
the haematopoietic stem cell (HSC) Id2 gene activation leads to the 
development of the lymphoid primed multipotent precursor (LMPP) and 
common lymphoid progenitor (CLP) that are restricted to the lymphoid lineage. 
Further commitment to the ILC lineage is established by upregulation of α4β7 
and downregulation of FLT3. The early ILC progenitor (EILP) initiates additional 
expression of IL-7Rα (CD127) and TCF1, but has low levels of ID2. The EILP 
can still develop in all ILC subsets, as well as NK cells. ILC differentiation 
proceeds to the common helper-like ILC subset (CHILP) that is characterized 
by high ID2 expression. Two subsets of CHILP can be discriminated, based on 
their expression of PLZF and PD1. Early PLZF-PD1- CHILP can give rise to all 
ILC subsets including LTi cells. Thereafter, CHILP cells upregulate the lineage-
defining transcription factors of the various ILC lineages. 
 
Figure 2. Regulation of ILC2 activation and effector functions of ILC2-derived 
cytokines. ILC2 integrate multiple signals and although they are primarily 
regulated by the alarmins IL-25, IL-33, and TSLP, ILC2 activation is also 
strongly influenced by γc-cytokines, lipid mediators, cell-cell interactions, and 
cell-surface molecules. Activated ILC2 are a prominent source of cytokines and 
other molecules, important for the regulation of inflammation and homeostasis. 
In red are the inhibitory receptor-ligand interactions. TSLP, thymic stromal 
lymphopoietin; VIP, vasoactive intestinal peptide; NMU, neuromedin; LXA4, 
Lipoxin A4; PGD2, prostaglandin D2; LTD2, Leukotrien D2, Areg, amphiregulin; 
Met-Enk, methionine-enkephalin. 
